Trial Profile
Safety and Effectiveness Trial of Apixaban Use in Association with Dual Antiplatelet Therapy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Aug 2019
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Aspirin; Clopidogrel
- Indications Coronary artery restenosis; Embolism and thrombosis
- Focus Adverse reactions
- Acronyms SAFE-A
- 26 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 28 Nov 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan record.
- 06 Jan 2015 New trial record